Treatment of Alzheimer disease

American Family Physician

Volumn 83, Issue 12, 2011, Pages 1403-1412

  Winslow, Bradford T ^a   Onysko, Mary K ^b   Stob, Christian M ^c   Hazlewood, Kathleen A ^b  

^a Swedish Family Medicine Residency   (United States)

^b UNIVERSITY OF WYOMING SCHOOL OF PHARMACY   (United States)

^c DENVER HEALTH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ESTROGEN; GALANTAMINE; GINKGO BILOBA EXTRACT; MEMANTINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SELEGILINE; TAU PROTEIN; TESTOSTERONE;

ACETYLCHOLINE BRAIN LEVEL; AGITATION; ALZHEIMER DISEASE; AMNESIA; AMYLOID PLAQUE; ANOREXIA; ARTICLE; CARDIOVASCULAR DISEASE; COGNITION; COMBINATION CHEMOTHERAPY; CONFUSION; DAILY LIFE ACTIVITY; DIARRHEA; DIET SUPPLEMENTATION; DIZZINESS; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GAIT DISORDER; GASTROINTESTINAL DISEASE; HEART ARRHYTHMIA; HUMAN; INSOMNIA; MENTAL DETERIORATION; NAUSEA; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; SIDE EFFECT; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

EID: 79959449517     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Thies W, Bleiler L; Alzheimer's Association. 2011 Alzheimer's disease facts and figures. Alzheimers Dement. 2011;7(2):208-244.
2. American Psychiatric Association. Practice Guideline for the Treatment of Patients with Alzheimer's Disease and Other Dementias. 2nd ed. Arlington, Va.: American Psychiatric Association; 2007.
3. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412-2414.
4. Knight Alzheimer's Disease Research Center. Clinical Dementia Rating. http://alzheimer.wustl.edu/cdr/AboutCDR/aboutcdr.htm. Accessed November 29, 2010.
5. Querfurth HW, LaFerla FM. Alzheimer's disease [published correction appears in N Engl J Med. 2011;364(6):588]. N Engl J Med. 2010;362(4):329-344.
6. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(3 suppl 2):S69-S74.
7. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.
8. Khachaturian AS, Zandi PP, Lyketsos CG, et al. Antihypertensive medication use and incident Alzheimer disease: the Cache County Study. Arch Neurol. 2006;63(5):686-692.
9. Gillette Guyonnet S, Abellan Van Kan G, Andrieu S, et al. IANA task force on nutrition and cognitive decline with aging. J Nutr Health Aging. 2007;11(2):132-152.
10. Rockwood K, Middleton L. Physical activity and the maintenance of cognitive function. Alzheimers Dement. 2007;3(2 suppl):S38-S44.
11. Daviglus ML, Bell CC, Berrettini W, et al. NIH State-of-the-Science Conference Statement: Preventing Alzheimer's Disease and Cognitive Decline. NIH Consens State Sci Statements. 2010;27(4):1-27. http://consensus.nih.gov/2010/docs/alz/alz_stmt.pdf. Accessed April 29, 2010.
12. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD005593.
13. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154.
14. National Institute for Health and Clinical Excellence (Great Britain); Social Care Institute for Excellence (Great Britain); National Collaborating Centre for Mental Health (Great Britain). Dementia: supporting people with dementia and their carers in health and social care. NICE clinical guideline 42. London, United Kingdom: National Institute for Health and Clinical Excellence; 2006.
15. Qaseem A, Snow V, Cross JT Jr, et al.; American College of Physicians/American Academy of Family Physicians Panel on Dementia. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med. 2008;148(5):370-378.
16. American Geriatrics Society. A guide to dementia diagnosis and treatment. http://dementia.americangeriatrics.org/. Accessed June 1, 2010.
17. California Workgroup on Guidelines for Alzheimer's Disease Management. Guideline for Alzheimer's disease management: final report. Los Angeles, Calif.: Alzheimer's Association; 2008.
18. Chertkow H. Introduction: the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, 2006. Alzheimers Dement. 2007;3(4):262-265.
19. Waldemar G, Dubois B, Emre M, et al. Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline. Eur J Neurol. 2007;14(1):e1-e26.
20. Caltagirone C, Bianchetti A, Di Luca M, et al. Guidelines for the treatment of Alzheimer's disease from the Italian Association of Psychogeriatrics. Drugs Aging. 2005;22(suppl 1):1-26.
21. Raina P, Santaguida P, Ismaila A, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med. 2008;148(5):379-397.
22. Thomson Reuters. Micromedex Healthcare Series: Drug Point Summary: Memantine. http://www.thomsonhc.com (subscription required). Updated periodically.
23. Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Dement Geriatr Cogn Disord. 2009;28(5):389-403.
24. Wentrup A, Oertel WH, Dodel R. Once-daily transdermal rivastigmine in the treatment of Alzheimer's disease. Drug Des Devel Ther. 2009;2:245-254.
25. Rainer M, Mucke HA, Krüger-Rainer C, Kraxberger E, Haushofer M, Jellinger KA. Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: cholinesterase inhibitors versus nootropics. J Neural Transm. 2001;108(11):1327-1333.
26. Schneider LS, Dagerman KS, Higgins JP, McShane R. Lack of evidence for the efficacy of memantine in mild Alzheimer Disease [published ahead of print April 11, 2011]. Arch Neurol. http://archneur.ama-assn.org/cgi/content/abstract/archneurol.2011.69 (subscription required). Accessed May 20, 2011.
27. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291(3):317-324.
28. Porsteinsson AP, Grossberg GT, Mintzer J, Olin JT; Memantine MEM-MD-12 Study Group. Memantine treatment in patients with mild to moderate Alzheimer's disease already receiving a cholinesterase inhibitor: a randomized, double-blind, placebo-controlled trial. Curr Alzheimer Res. 2008;5(1):83-89.
29. Birks J, Flicker L. Selegiline for Alzheimer's disease. Cochrane Database Syst Rev. 2003;(1):CD000442.
30. Ballard C, Waite J. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev. 2006;(1):CD003476.
31. Sultzer DL, Davis SM, Tariot PN, et al.; CATIE-AD Study Group. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. Am J Psychiatry. 2008;165(7):844-854.
32. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial. BMJ. 2005;330(7496):874.
33. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med. 2007;146(11):775-786.
34. Hogervorst E, Yaffe K, Richards M, Huppert FA. Hormone replacement therapy to maintain cognitive function in women with dementia. Cochrane Database Syst Rev. 2009;(1):CD003799.
35. Rigaud AS, André G, Vellas B, Touchon J, Pere JJ; French Study Group. No additional benefit of HRT on response to rivastigmine in menopausal women with AD. Neurology. 2003;60(1):148-149.
36. Isaac MG, Quinn R, Tabet N. Vitamin E for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev. 2008;(3):CD002854.
37. Aisen PS, Schafer KA, Grundman M, et al.; Alzheimer's Disease Cooperative Study. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. JAMA. 2003;289(21):2819-2826.
38. Reines SA, Block GA, Morris JC, et al.; Rofecoxib Protocol 091 Study Group. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology. 2004;62(1):66-71.
39. Tabet N, Feldmand H. Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev. 2003;(2):CD004031.
40. Tabet N, Feldman H. Indomethacin for the treatment of Alzheimer's disease patients. Cochrane Database Syst Rev. 2002;(2):CD003673.
41. Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer's disease. Aging Clin Exp Res. 2009;21(2):102-110.
42. Feldman HH, Doody RS, Kivipelto M, et al.; LEADe Investigators. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology. 2010;74(12):956-964.
43. Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T. Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease [published ahead of print November 17, 2009]. Neurobiol Aging. http://www.sciencedirect.com/science/article/pii/S019745800900339X (subscription required). Accessed May 23, 2011.
44. Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. Cochrane Database Syst Rev. 2003;(3):CD001015.
45. Hudson S, Tabet N. Acetyl-L-carnitine for dementia. Cochrane Database Syst Rev. 2003;(2):CD003158.
46. Tan RS, Pu SJ. A pilot study on the effects of testosterone in hypogonadal aging male patients with Alzheimer's disease. Aging Male. 2003;6(1):13-17.
47. Cherrier MM, Matsumoto AM, Amory JK, et al. Testosterone improves spatial memory in men with Alzheimer disease and mild cognitive impairment. Neurology. 2005;64(12):2063-2068.
48. Lu PH, Masterman DA, Mulnard R, et al. Effects of testosterone on cognition and mood in male patients with mild Alzheimer disease and healthy elderly men. Arch Neurol. 2006;63(2):177-185.
49. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122.
50. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009;(1):CD003120.
51. Yancheva S, Ihl R, Nikolova G, Panayotov P, Schlaefke S, Hoerr R; GINDON Study Group. Ginkgo biloba extract EGb 761(R), donepezil or both combined in the treatment of Alzheimer's disease with neuropsychiatric features: a randomised, double-blind, exploratory trial. Aging Ment Health. 2009;13(2):183-190.
52. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.
53. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):270-279.
54. Neugroschl J, Sano M. Current treatment and recent clinical research in Alzheimer's disease. Mt Sinai J Med. 2010;77(1):3-16.